Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Dermatologic 1

Conditions

Plasmacytoma 1Multiple Myeloma 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × silmitasertib × Clear all
NCT03897036 2025-05-20

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Senhwa Biosciences, Inc.

Phase 1 Completed
25 enrolled 9 charts
Dermatologic

Carcinoma, Basal Cell

NCT01199718 2011-06-15

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Cylene Pharmaceuticals

Phase 1 Unknown
22 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡